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Recent healthcare efforts have targeted patient engagement as a means to improve medical 
outcomes and reduce the healthcare costs of chronic conditions. This pilot study analyzed 
engagement levels among patients who underwent genetic counseling for Gastrointestinal (GI) 
cancer risk assessment, and examined the feasibility of implementing engagement measures in 
an outpatient specialty clinic. We hypothesized that undergoing genetic counseling would 
empower patients and result in increased engagement scores. Patients seen at the UPMC 
Hereditary GI Tumor Program were asked to complete a patient engagement measure, the 
Altarum Consumer Engagement (ACE), prior to undergoing genetic counseling. Post-
appointment ACE measures were completed for each participant three months after enrollment 
via telephone. Paired t-test analysis was conducted to assess changes in the ACE scores before 
and after genetic counseling. In the sample of 38 participants, the ACE Measure scores were 
found to increase significantly after having genetic counseling (p = 0.0342). No statistically 
significant differences were found in ACE scores between participants recently diagnosed with 
cancer and those with a past personal history or a family history of cancer (p = 0.2042). The 
implementation of engagement measures in the clinical setting is feasible, and may assess the 
impact of genetic counseling on healthcare efficacy in patients suspected to have a genetic cancer 
susceptibility. Identifying novel approaches for patient activation is of public health significance, 
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both in improving patient outcomes and lowering healthcare cost. Future research is ongoing to 
investigate whether improved patient engagement correlates to lifestyle modifications that reduce 
cancer risk. 
vi 
TABLE OF CONTENTS 
1.0 STUDY OVERVIEW ......................................................................................................... 1 
2.0 LITERATURE REVIEW .................................................................................................. 2 
2.1 CANCER .............................................................................................................. 2 
2.1.1 Acquired Cancer ........................................................................................... 2 
2.1.2 Cancer Risk Factors ..................................................................................... 3 
2.1.3 Adherence to Lifestyle Recommendations.................................................. 3 
2.1.4 Lifestyle Behaviors on Hereditary Cancers ................................................ 4 
2.2 ENGAGEMENT ............................................................................................. 5 
2.2.1 Patient Engagement ...................................................................................... 5 
2.2.2 Benefits of Engaged Patients ........................................................................ 6 
2.2.3 Changing Role of Patients and Healthcare ................................................. 7 
2.3 ENGAGEMENT MEASURES ...................................................................... 8 
2.3.1 Overview of Engagement Measures ............................................................ 8 
2.3.2 The ACE Measure......................................................................................... 9 
2.4 GENETICS ......................................................................................................... 11 
2.4.1 High-Risk Cancer Individuals ................................................................... 11 
2.4.2 Genetic Counseling ..................................................................................... 12 
2.5 OUTCOMES ...................................................................................................... 13 
2.5.1 Patient Outcomes ........................................................................................ 13 
2.5.2 Genetic Counseling Outcomes ................................................................... 14 
2.5.3 Impact of Genetic Test Results .................................................................. 17 
3.0 MANUSCRIPT ................................................................................................................. 18 
3.1 INTRODUCTION ............................................................................................. 18 
3.2 METHODS ......................................................................................................... 20 
3.2.1 Participants .................................................................................................. 20 
3.2.2 Eligibility Criteria ....................................................................................... 21 
3.2.3 Recruitment ................................................................................................. 21 
3.2.4 Instrument ................................................................................................... 21 
3.2.5 ACE Measure Scoring ................................................................................ 23 
3.2.6 Procedures ................................................................................................... 25 
3.2.7 Data Analysis ............................................................................................... 27 
3.3 RESULTS ........................................................................................................... 27 
3.3.1 Demographics .............................................................................................. 28 
3.3.2 ACE Measure across all Participants ....................................................... 30 
3.3.3 ACE Measure between Recent Cancer Diagnosis and Family History . 33 
3.3.4 ACE Measure between Male and Female Participants ........................... 33 
3.3.5 Pre and Post ACE Measure Changes by Participant Age ....................... 34 
3.4 DISCUSSION ..................................................................................................... 34 
3.4.1 Research Recommendations and Limitations .......................................... 38 
3.5 CONCLUSION .................................................................................................. 39 
vii 
4.0 RESEARCH SIGNIFICANCE TO GENETIC COUNSELING AND PUBLIC 
HEALTH ......................................................................................................................... 39 
5.0 PUBLIC HEALTH ESSAY ............................................................................................. 41 
5.1 INTRODUCTION ............................................................................................. 41 
5.2 PARTICIPANTS ............................................................................................... 43 
5.3 RESULTS ........................................................................................................... 45 
5.4 DISCUSSION ..................................................................................................... 47 
5.5 CONCLUSION .................................................................................................. 51 
APPENDIX A: DOCUMENTATION FOR METHODOLOGY ........................................... 53 
APPENDIX B: DATA DISTRIBUTION AND STATA OUTPUT ........................................ 70 
APPENDIX C: PUBLIC HEALTH CHAPTER DOCUMENTATION ................................ 83 
BIBLIOGRAPHY ....................................................................................................................... 90 
viii 
 LIST OF TABLES 
Table 1. Participant Demographic Data ........................................................................................ 29 
Table 2. Participants Raw Data Scores ......................................................................................... 30 
Table 3. Pre-Commitment vs. Post-Commitment ACE Scores .................................................... 32 
Table 4. Pre-Navigation vs. Post-Navigation ACE Scores ........................................................... 32 
Table 5. Pre-Informed Choice vs. Post-Informed Choice ACE Scores ........................................ 32 
Table 6. Pre-Total vs. Post-Total ACE Scores ............................................................................. 32 
Table 7. Participant Cancer Status and Lifestyle Behavior Changes ............................................ 45 
Table 8. Failed to Change and Succeeded to Change Total ACE Score Comparison .................. 46 
Table 9. Failed Change and Successful Change ACE Domains Summary .................................. 46 
ix 
LIST OF FIGURES 
  
Figure 1. ACE Measure Domains ................................................................................................. 23 
Figure 2. ACE Measure Score Interpretation ............................................................................... 24 
Figure 3. Protocol Flowsheet ........................................................................................................ 26 











♦ Andrea Durst, MS, DrPH, LCGC, Assistant Professor, Department of Human Genetics, 
Graduate School of Public Health, University of Pittsburgh 
 
♦ Eve Karloski, MS, CGC, Department of Medicine Division of Gastroenterology, 
Hepatology, and Nutrition, University of Pittsburgh  
 
♦ The UPMC Health Plan Team, especially:   
o Jamie L. William, RRT, Program Manager, Commercial Products, University of 
Pittsburgh Medical Center 
 
o Bill Gille, Program Coordinator, UPMC Health Plan, Health Promotion, 




1.0  STUDY OVERVIEW 
This study aims to analyze patient engagement outcomes in individuals who are suspected to 
have a genetic cancer susceptibility and who have undergone genetic counseling. This pilot study 
is valuable in furthering the understanding of patient engagement in their health and in the 
healthcare system. Studying the outcomes of individuals with and without a cancer diagnosis 
who have some genetic susceptibility, can help to identify improved means of engaging patients, 
promoting lifestyle modifications, and ultimately, improve both cost effectiveness and patient 
satisfaction. Better understanding of such associations will have particular influence on 
stakeholders including patients, medical professionals, and healthcare systems.  
This study examined the level of patient engagement in individuals who were referred for 
genetic counseling because they have a personal cancer diagnosis or have a family history of 
cancers, and are thereby suspected to have some genetic cancer susceptibility.  
The hypothesis tested in this study is that genetic counseling will empower patients and result in 
increased engagement scores (ACE Measure) over time.   
The specific aims of this study included:  
1. To analyze changes in individuals’ engagement in their health (ACE Measure) before and 
after undergoing genetic counseling. 
2. To compare the pre and post ACE Measures between patients who have a current 
diagnosis of cancer and those patients who have a past personal history of cancer or a 
family history of cancer.   
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This pilot study also assessed the feasibility of implementing patient engagement measures in the 
clinic and evaluated patient recruitment methods, retention, and data analysis approaches for 
future research studies.  
2.0  LITERATURE REVIEW 
2.1 CANCER 
2.1.1 Acquired Cancer 
Cancer is a leading cause of death worldwide, accounting for one in eight deaths globally.1 In the 
United States alone, more than 1.7 million new cancers are estimated to be diagnosed in 2017.2 
Recent epidemiological evidence however, suggests that up to 50% of all cancers could 
potentially be prevented through lifestyle modifications.3 In more than 20% of cancer cases, 
unhealthy body weight is a primary contributor to the diagnosis. Smoking is also thought to 
contribute to two thirds of cancer deaths in the US, and could be prevented with lifestyle 
modifications.4 Numerous organizations including the US Department of Health and Human 
Services, the American Cancer Society, the World Research Fund, the Centers for Disease 
Control, and the American Institute for Cancer Research have developed several 
recommendations for lifestyle behaviors. Such lifestyle behaviors include avoidance of tobacco 
products, restriction of alcohol intake, maintaining a healthy weight, exercising regularly, and 
eating ample servings of fruits and vegetables.1,5–9 Adherence to such guidelines have been 
shown to reduce an individual’s breast cancer risk by 22%, colon cancer risk by 52%, and reduce 
overall cancer risk by at least 17%.5,4 Further research on the empowerment of patients in their 
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own health behaviors and in the utilization of the healthcare system to support a healthy lifestyle 
is important to the improvement of public health as a whole.  
2.1.2 Cancer Risk Factors 
Today, approximately two thirds of individuals survive at least five years after a cancer 
diagnosis. Many factors can account for this increase in survival, including improved cancer 
treatments and the availability of effective screening/early detection strategies for many cancers. 
Additional factors such as personal lifestyles can also be taken into consideration.10 
Physical inactivity and its association with obesity, and tobacco usage are two of the 
major risk factors known to be associated with cancer.11 In fact, individuals with a body mass 
index (BMI) of over 25kg/m2 have a 24% increased prevalence of colorectal cancers.12 Over 
25% of all cancer deaths in the United States are estimated to be caused by smoking. Tobacco is 
traditionally associated with lung cancer, but also has been linked to colorectal, bladder, and 
esophageal adenocarinomas.13 
2.1.3 Adherence to Lifestyle Recommendations 
Recent National Comprehensive Cancer Network (NCCN) Guidelines for Smoking Cessation 
suggest that the most effective approach in aiding patients to quit smoking is the combination of 
pharmacologic therapy, such as nicotine patches, in addition to counseling. The NCCN 
guidelines also encourage healthcare providers’ support and call for an increased discussion 
about the risks of smoking to decrease relapse rates and further engage patients in their own 
health.13 Yet, despite growing evidence surrounding the impact of behaviors on health and 
cancer risk, studies have found that the majority of patients tend to attribute increased risk with 
uncontrollable and broad factors including stress, bad luck, and genetics.3,6 
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Various studies have determined that adherence to the recommended guidelines put forth 
by organizations such as the American Cancer Society and World Cancer Research Fund is 
associated with statistically significant reduction in cancer incidence and mortality. A systematic 
review (2016)14 performed meta-analysis of twelve studies that analyzed patience adherence to 
recommended guidelines and their cancer outcomes over time. The twelve studies reviewed were 
international and comprised of large sample cohorts with ample statistical power, and a 
timeframe of 7-14 years. Compliance with nutritional and physical activity guidelines alone was 
found to decrease up to 61% of overall cancer and mortality incidence. Participants with high 
adherence were also found to have lower risk for some site-specific cancers including breast 
cancer, endometrial cancer, and colorectal cancer by an average of 27 – 57%.14 
2.1.4 Lifestyle Behaviors on Hereditary Cancers 
While lifestyle behaviors have been shown to reduce cancer risk in the general population, fewer 
studies are available that analyze the effect of behavior on hereditary cancers. Hereditary cancer 
syndromes, such as hereditary breast and ovarian cancer (BRCA1 and BRCA2 genes) and Lynch 
syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM genes) confer an increased risk for the 
development of specific cancers. For the hereditary breast and ovarian cancer genes, the risk for 
breast cancer in a woman’s lifetime can be up to 70%, and up to 40% for ovarian cancer.15 
Lynch-related genes mutations result in a risk for colorectal cancer that can be as high as 69%.16 
While these risks are significantly increased compared the general population, they are not 
100%. Due to the difference in penetrance and cancer incidence between individuals, even 
within the same family, it is likely that risk-modifying factors contribute to cancer 
development.16–18  
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Previous research has found that such lifestyle factors can include obesity and tobacco 
usage. The incidence of breast cancer has been found to be lower in BRCA1/2 mutation carriers 
who report high levels of physical activity, while a diet high in fruit and vegetables has been 
shown to reduce cancer risk in individuals with Lynch syndrome.20–22 Likewise, smoking has 
been associated with higher cancer development rates in individuals with hereditary cancer 
predispositions.23  
One study observed lifestyle behaviors among individuals at risk for Lynch syndrome. 
The study of 429 participants looked both at individuals who had a colorectal cancer diagnosis 
and unaffected, at-risk relatives. The study found that despite all participants being at risk for a 
hereditary cancer predisposition, individuals who had not had a previous cancer diagnosis were 
more likely to have poor lifestyle behaviors compared to individuals who had previously been 
diagnosed with cancer.24 While all patients in this study were at increased risk for hereditary 
cancer, the majority of lifestyle modifications took place only after a cancer diagnosis. The 
impact of lifestyle behaviors on hereditary cancer compared to sporadic cancers, therefore, can 
be complicated by patient risk perceptions. Furthermore, the need for additional research 
surrounding risk-reducing behaviors specific to hereditary cancers has led to several clinical 
trials currently underway (clinicaltrails.gov).   
2.2 ENGAGEMENT 
2.2.1 Patient Engagement 
Engagement of individuals within the healthcare system is of particular importance for 
understanding and improving the patient experience. The definition of engagement however, 
varies widely in terms of the behaviors, knowledge base, skills, and attitudes that it is thought to 
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encompass.25 Mahmud (2004)26 for instance, describes engagement as an organizational method 
that incorporates patient input into the decision making process. Dearing and colleagues (2005)27 
consider engagement to describe a client-therapist relationship, in which treatment and 
management options are reached through joint effort. Other definitions incorporate the idea of 
informal discussion, self-care capability, and the utilization of tools such as the web-based 
patient portals in order to describe engagement.26,28 A more comprehensive definition for 
engagement, which will be used for the purpose of this study, is described by Gruman et al.28 as 
the “actions individuals must take to obtain the greatest benefit from the health care services 
available to them.” The Gruman definition encompasses the various ways that engagement can 
be considered, from personalized action and communication, to utilization of various resources 
both within and outside of the healthcare system. 
2.2.2 Benefits of Engaged Patients 
The measurement of patient engagement can have multiple effects on a health care organization. 
Determining a patient’s involvement in their health can allow for identification of targeted 
populations, segmentation, and evaluation of existing interventions. Participation rates can also 
provide key information about risk stratification for targeted interventions, and help to facilitate 
customized care pathways, and provide enhanced care both at an individual and community 
level.25 
Patient engagement has been linked to a range of beneficial outcomes not only for 
patients, but for healthcare organizations as well. Patients who had high engagement levels 
reported higher satisfaction with their healthcare, and recover faster from illnesses. High levels 
of engagement were also correlated with improved medical adherence, shorter lengths of stay in 
hospitals, and better long term quality of life. Additionally, patients who are considered to be 
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highly engaged in their health and in the medical system have half the rate of medical errors 
compared to those with low-levels of participation.29 
From the provider’s perspective, patient engagement has been shown to afford significant 
cost reduction in healthcare. When patients are engaged in their health and in the healthcare 
system finances and resources are preserved through the avoidance of unnecessary surgeries, 
better adherence to medical management, and the prevention of medical errors. Patient 
participation can also reduce healthcare costs by choosing options based on an individual’s 
preference, rather than simply being provided with the standard of care approach.25 High levels 
of patient involvement lead to safer, more effective, and less expensive healthcare overall. As 
such, the active role of patients in managing their health is important to increase satisfaction, 
successful outcomes, and developing economically sustainable healthcare systems. 
2.2.3 Changing Role of Patients and Healthcare 
Patient engagement is seen to have a positive effect on both the patient experience and on the 
health care systems. Now more than ever, patients have a diverse and expanding role within the 
medical field. No longer are patients simply passive recipients of care, but rather patients are 
encouraged to participate in their own health as empowered consumers.25 Today, patients often 
act as advocates for new treatments, management, and personalized decision making. Patient 
involvement is also essential in traversing interdisciplinary collaboration among healthcare 
professionals and specialty facilities. 
The role of patients in their health is not the only change occurring within the healthcare 
system. As medical advancements, treatments, and technology continue to develop, so too have 
the settings and expectations of the medical practice. Patients can now utilize online resources, 
comparative tools, and rating systems to determine the best care for their personal needs. The 
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medical field has become a highly competitive domain under constant scrutiny of patients and 
healthcare professionals are under pressure to provide services tailored to individuals, and not 
merely offer generalized treatments.30 The changing role of the patient and the environment of 
the medical field also influences the ways in which patients interact with the healthcare system 
and in their opportunities for engagement in their own health.25,29 
The role that healthcare plays in an individual’s lifestyle; however, is limited by the 
interactions providers have with their patients. For many Americans, the healthcare system is 
viewed as a reactive model, in which help is sought only after becoming ill. Thus, patients may 
spend only a few hours a year with healthcare providers to treat the symptoms of significant 
underlying behavioral concerns such as obesity or smoking. The other five thousand waking 
hours each year, however, are left to individual choices, surrounding behaviors that can 
profoundly affect their health.31 The ability to engage patients in their own health therefore, is 
essential to the reduction of healthcare spending and to the improvement of public health and 
healthcare overall. 
2.3 ENGAGEMENT MEASURES 
2.3.1 Overview of Engagement Measures 
The changing role of patients and the evolving expectations of the healthcare system allow for 
different ways to become more involved in patient well-being. However, not all patients are able 
to take advantage of such changes. As the role of the patient expands, so too do the skills and 
knowledge base required to navigate the system. When considering patients’ participation in 
their own health, it is important to note the differences in socio-demographics, individual 
experiences, and social norms. The ability to acquire up-to-date health information, to participate 
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in healthy behaviors, to afford medical management, to follow treatment prescription, or to 
interact with healthcare professionals, are all factors that can affect a patient’s engagement.29 
Recognizing these differences is vital to better serve individuals with unique perspectives and 
abilities. To understand patient engagement therefore, demands consideration of a 
comprehensive outlook on a variety of factors such as a patient’s personal awareness, skill set, 
confidence, and experience within the healthcare system.29 Patient engagement measures are 
valuable to improving patient experiences through identifying problematic aspects of health care 
disparities in order to develop improved delivery of care and to meet patient expectations. 
While engagement is important to the improvement of patient experience and healthcare 
services, there are few validated methods to assess the role of patients in their health and the 
health system. It is especially difficult to create valid assessment measures in the rapidly 
changing healthcare environment and incorporation of developing technology. Most 
measurement tools that are available are specific to one aspect of patient involvement, typically 
measuring only autonomy, information preferences, or decision making. Other tools cover 
multiple domains of engagement, but are specific to management of a particular disease.25 The 
current tools are often inadequate in addressing the factors of engagement that encompass the 
skills patients need today in order to take advantage of technology and information sources, such 
as online patient portal engagement, or comparison tools for healthcare systems.25,29,32 Current 
measures are mainly unidimensional, highly specific, or meant for disease management and do 
not incorporate technological health care involvement. 
2.3.2 The ACE Measure 
A new measure, called the Altarum Consumer Engagement (ACE) Measure™ (June 2015), was 
created to address some of the limitations in the current engagement measurement tools. The 
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purpose of the ACE measure is to improve the health care experience through understanding the 
engagement of patients. The ACE strives to consider patient lifestyle behaviors, decision 
process, and the use of technology and resources in education and involvement of 
individuals.29,32 
The ACE measure is a tool designed to evaluate the engagement of individuals in their 
healthcare. The ACE measure used for this study involves 12 questions, which evaluate three 
domains of health, including: Commitment, Informed Choice, and Navigation.32 
• The Commitment domain reviews an individual’s proactive behaviors and self-care 
habits. Commitment scores reflect the level of consistency in health habits and health 
practices for an individual over time. 
• The Informed Choice domain encompasses the types of resources an individual may 
reference when making health decisions. The Informed Choice score refers to the actions 
taken to evaluate the medical system when making choices about available providers or 
services. 
• The Navigation domain summarizes an individual’s ability to communicate within the 
healthcare system. Navigation scores refer to the individual experiences, and reflects 
personal views and impressions about the healthcare system.32 
The ACE measure was created with the purpose of expanding the way in which patient 
engagement is measured and understood, as well as to incorporate modern information sources 
and technology available to patients. ACE can provide valuable information about necessary 
improvements within the system, but also can enable medical professionals to help patients 
become more confident and involved in their own health through the identification of strengths 
and weaknesses in their Commitment, Informed Choice, and Navigation scores.  As such, ACE 
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can also be useful for medical professionals to evaluate the abilities of patients in making 
decisions, and the type and quantity of support that may be needed for each patient.32 
The ACE measure can be used not only on an individual scale, but also on a population 
and community level. Within the population at large, the ACE tool can measure a population’s 
overall engagement, which can provide insight for designing more efficient strategies for 
community outreach and advocacy. The measure can also be used as a metric to monitor changes 
and assess the impact of interventions over time in a given population, which can offer valuable 
information for evaluations and revisions. The ACE can then identify subpopulations at the 
community level, and target health interventions based on specific population involvement for 
more efficient and satisfying management.32 The ACE measure therefore, has a variety of 
functions and potential uses for bettering both patient experience as well as healthcare systems at 
larger population levels. 
2.4 GENETICS 
2.4.1 High-Risk Cancer Individuals 
Approximately 10% of all cancer diagnoses are due to a genetic predisposition.33 These cancers 
are mainly caused by a single genetic change which can be passed through the generations of a 
family. These genetic changes can significantly increase the risk for developing cancer. For 
example, colorectal cancer is the third most common cancer in the United States, and 
approximately 5-10% of all diagnoses are caused by a hereditary syndrome. While the general 
population lifetime risk for developing colorectal cancer is about 5-6%, an individual with a 
genetic predisposition may have an increased lifetime risk as high as 100% if untreated.34,35 
Individuals with an extensive family history of certain cancer types, or an identified genetic 
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predisposition therefore, are considered to be at a higher risk for cancer development compared 
to the general population.   
Genetic testing is often offered to individuals who are thought to have increased risk in 
order to better address management and screening options. Patients considered to be at high-risk 
are typically identified through their personal cancer history, or through identification of multiple 
family members with cancer. Genetic counselors can help facilitate the process of risk education 
and genetic testing for hereditary conditions.  
2.4.2 Genetic Counseling 
Genetic counseling is a specialized medical profession which aims to promote patient 
understanding of the complex genetic and genomic components of disease, as well as to provide 
psychosocial support for each patient. The most recent definition of genetic counseling was 
developed by the Genetic Counseling Definition Task Force of the National Society of Genetic 
Counselors in 2006:  
“Genetic counseling is the process of helping people understand and adapt to the medical, 
psychological and familial implications of genetic contributions to disease. This process 
integrates the following: 
• Interpretation of family and medical histories to assess the chance of disease 
occurrence or recurrence. 
• Education about inheritance, testing, management, prevention, resources and 
research. 
• Counseling to promote informed choices and adaptation to the risk or 
condition.”36 
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Since its inception over 40 years ago, genetic counseling has evolved to serve multiple roles 
including that of an educator, supporter, medical liaison, resource provider, and interdisciplinary 
team member. Genetic counselors work in an assortment of specialty services specific to the 
genetics and genomics involved in each discipline. Such fields can include oncology, 
cardiovascular, neurology, pediatric, prenatal, research, and diagnostic laboratory services.37 
2.5 OUTCOMES 
2.5.1 Patient Outcomes 
In healthcare research, an “outcome” can be defined as what happens to a patient, or an end 
result, as a direct consequence of their encounters with the healthcare system.37 In order to 
measure outcomes, a valid and reliable assessment tool can be utilized to track end results or 
changes over time. Tracking patient outcomes is important for quality assurance purposes and 
improvement. 
Since the Patient Protection and Affordable Care Act of 201038, patient outcomes have 
become even more important to assess within the healthcare system. The Affordable Care Act 
(aka: Obamacare) has implemented several new considerations revolving around patient centered 
outcome research. For example, Title I, Subtitle A: Sec. 1001 (as modified by Sec. 10101) 
requires the Secretary of Health and Human Services to develop reporting requirements to track 
patient improved health outcomes, prevention of hospital readmissions, reduction of medical 
errors, and the promotion of patient wellness and health. Furthermore, healthcare systems 
including the Centers for Medicare and Medicaid Services (CMS) have established a mandatory 
reporting system, the Physician Quality Reporting System (PQRS), for the identification of a 
comprehensive set of patient outcome measures.  
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In order to receive full reimbursement of healthcare services, the PQRS requires 
professionals and group practices to report patient outcomes such as patient perceptions and 
timeliness of care for quality assurance purposes. In 2015, the program initiated a negative 
payment adjustment to those professionals who failed to report satisfactory outcome measures, 
resulting in a 2% decrease in all reimbursements through CMS.39 
As a result of the Affordable Care Act, patient outcomes are now emphasized measures 
of quality institutions and are being rapidly integrated into clinical and medical research. Soon, 
many more private and public practices may be asked to demonstrate improved patient outcomes 
as well.37 This establishment drives the need for both valid measure tools, as well as defined 
expected outcome values in a variety of professional fields. 
2.5.2 Genetic Counseling Outcomes 
Genetic counselors are considered valuable members to many clinical and research teams as a 
means of enhancing patient care as well as improving time management and patient satisfaction, 
while concurrently decreasing liability and overall cost through reduction of repetitive or 
inappropriate testing.40 To date, however; there is limited information concerning the impact of 
genetic counseling on patient outcomes. Furthermore, despite recent laws toward defined patient 
outcome measures, genetic counseling lacks research and establishment of a set of evidence-
based outcomes expected from the profession.37 
The identification of outcome measures unique to genetic counseling services has since 
become a priority for the profession. In one of the first studies to address the growing need for 
defined expectations in the genetic counseling profession, Redlinger-Grosse, et al.37 analyzed the 
results of five focus groups aimed at developing a comprehensive list of outcomes based upon 
the Reciprocal-Engagement Model (REM). The REM is a specific practice model that outlines 
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the mutual participation of patients and genetic counselors in the education process and in the 
understanding and application of new information.  
 Four major outcomes were described, including: 
1.     Patient Knowledge 
2.     Decision-Making 
3.     Patient Satisfaction 
4.     Psychological Adaptation 
While no defined patient outcomes are universally tracked for genetic counselors, the four major 
themes addressed in the Redlinger-Grosse, et al.37 study provide a framework of anticipated 
benefits. Ensuring patient knowledge is the foundation of genetic counseling training, both 
through translation of patient’s results and information into clear, practical material, and in being 
able to convey specific, complex genetic information in understandable ways. One of the aims of 
genetic counseling is likewise to enable patients to make informed decisions.37  
Through individualized counseling, patients are supported to choose the medical and 
health decisions that are best for them. Consequently, patient satisfaction can also be expected to 
improve with genetic counseling, as patients may feel more informed and in control of their 
decisions and health management than standard healthcare practices alone can offer. Finally, the 
counseling component inherent in genetic counseling is a vital aspect of the profession, which 
encourages further exploration of the emotional effect genetic information may create in the 
patient. The failure to address the emotional consequences of genetic information for an 
individual may even ultimately act as a barrier in an individual’s capacity to process the 
information.41 It could be anticipated then, that genetic counseling can benefit the emotional 
wellbeing of the patient through reducing anxiety, and enabling adaption and open 
communication for the individual and their families.37 
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Studies that analyze the impact of genetic counseling suggest that patients do have a 
better understanding of cancer risks and in some cases, may be more likely to participate in 
cancer screenings. In one study, genetic counseling outcomes and patient empowerment were 
measured in patients with complex, multifactorial conditions. The study determined that there 
were statistically significant increased levels of empowerment in patients one month after their 
genetic counseling appointment. The changes observed however, were not influenced by the 
provision of genetic test results, as no genetic testing was provided for the participants. The 
results of the study were statistically significant and had a large effect size observed, with 
clinically meaningful differences.41,42 Similarly, a 2016 study reviewed outcomes in 120 
individuals with serious mental health illnesses and found that genetic counseling improved both 
patient knowledge of the genetic components of disease, as well as improved accuracy in risk 
perception when compared to the provision of only an educational booklet.43 
In another study, genetic counseling involvement in pediatric care was measured for 
medical adherence in a study population of approximately 200 participants. The study found that 
the inclusion of a genetic counselor in pediatric appointments resulted in improved adherence to 
medical management in a statistically significant manner.44 
Furthermore, the psychological impact of genetic counseling for familial cancer was 
analyzed through meta-analysis. This study, published in 200645, performed a systematic review 
of the literature to examine the effect of genetic counseling on patient knowledge and 
psychological adaptation in 21 studies. The study concluded that genetic counseling did improve 
patient knowledge of cancer genetics, but had no impact, positive or negative, on the anxiety, 
distress, depression, or cancer-specific worry examined in the trials. Further investigation was 
strongly recommended in order to validate such findings and to analyze additional outcomes 
measures.45  
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In addition, a 2016 study of Australian patients looked at changes in screening and 
management choices made by individuals specific to genetic testing results. The study found that 
genetic information provided through genetic counselors impacted individual behavior in those 
individuals who were identified with a genetic predisposition to colorectal cancer. Those 
individuals with a genetic predisposition who were seen by a genetic counselor were more likely 
to undergo colonoscopy screening and were also more likely not to smoke.46 
Such conclusions indicate the need for more extensive research on the effects of not only 
genetic information, but of the entire genetic counseling process for the purpose of identifying 
improved methods of patient engagement.  
2.5.3 Impact of Genetic Test Results  
The association between genetic predispositions and disease has been an exciting new approach 
to health and management for patients. Genetic risk information is an exciting tool for healthcare 
providers to help individuals to change lifestyle behaviors. For some patients, genetic 
information may influence individuals to increase their screening for cancer, while for others, it 
may provoke behavior changes such as weight lost or diet modifications. In practice, however, 
research has found that the use of genetic information alone has little to no impact on patient 
behavior change.41  
Several literature reviews have reported on the impact genetic information can have on 
individual lifestyle and psychological state. One extensive literature review published in 2008 
examined the effect of genetic information on patient’s perceived risk, psychological, and 
behavioral changes. A total of 35 articles and 30 studies were analyzed and the review concluded 
that the genetic information had no significant impact on psychological adjustment regardless of 
genetic test results, and that only a minor improvement of cancer-reducing behavior modification 
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was observed.35 Another recent meta-analysis by Hollands et al.47 also reviewed 18 studies 
concerning smoking cessation, diet, and physical activity changes in patients provided with 
genetic predisposition information. The analysis demonstrated that genetic risk information had 
little to no effect on lifestyle modifications for patients with genetic predispositions. Genetic 
information alone therefore, appears to have little to no effect on patient behavior.  
3.0  MANUSCRIPT 
3.1 INTRODUCTION 
In healthcare, an “outcome” can be defined as what happens to a patient as a direct consequence 
of their encounters with the healthcare system.37 Patient outcomes are now emphasized measures 
of quality institutions, and are being rapidly integrated into clinical and medical research. Since 
the Patient Protection and Affordable Care Act (ACA) of 2010, the assessment of patient 
outcomes has become even more important, with mandatory reporting of health outcomes 
including prevention of hospital readmissions, reduction of medical errors, and the promotion of 
patient wellness efforts.38 Additional private and public practices may soon be required to 
demonstrate improved patient outcomes as well.37 Such legislation drives the need for defined 
outcome measures across a variety of healthcare fields.  
The identification of outcome measures unique to the field of genetic counseling has 
likewise become a priority of the profession.37 Previous research on the impact of genetic 
counseling suggests that patients have an improved understanding of cancer risk and increased 
patient empowerment. In one study, outcomes in over one hundred individuals with serious 
mental health illnesses found that genetic counseling improved both patient knowledge of the 
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genetic components of disease, as well as improved accuracy in risk perception compared to an 
educational booklet.43 Genetic counseling outcomes have also been measured in patients with 
complex, multifactorial conditions in the absence of genetic testing. Over 140 subjects were 
assessed by psychological state and self-efficacy measures before and after genetic counseling, 
and found statistically significant increases in empowerment levels one month after undergoing 
genetic counseling.41,42 Further genetic counseling outcomes identified through previous research 
suggest improved medical adherence in both pediatric and cancer settings, and increased patient 
knowledge of cancer genetics.44,45 While the impact of genetic counseling has shown to have 
beneficial patient outcomes, further research on expectations unique to genetic counseling and 
defined, measurable outcomes is critical in the evolving setting of healthcare.  
 The ability to measure and define evidence-based outcomes is significant not only to 
assure quality, but also to obtain key information about risk stratification for customized care 
pathways.25 In particular, patient engagement as an outcome has become an attractive new 
measure for clinicians and healthcare providers to evaluate their patient population. Patient 
engagement is defined as the actions an individual must take in order to elicit the greatest 
possible health benefit from the resources available to them.28 Within the healthcare system, 
patient engagement outcomes can be seen to influence both individual outcomes, as well as 
healthcare costs at a community level. Patients with higher engagement levels reported not only 
having higher satisfaction, but also had improved medical outcomes, faster recoveries, and 
overall better quality of life. In addition, engaged patients were found to reduce healthcare cost 
through avoidance of unnecessary surgeries, decreased medical errors, and increased adherence 
to medical management.25,29 
Genetic counselors have been shown to be capable of improving patient knowledge and 
empowerment, however we could not identify any reported research on the impact of genetic 
counseling on patient engagement. In this study, it was hypothesized that genetic counseling 
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activates patients in their health and results in increased patient engagement scores. In order to 
measure patient engagement, the Altarum Consumer Engagement (ACE) Measure™ was 
utilized. The ACE Measure is a new, validated tool designed to quantify patient engagement 
levels through the consideration of an individual’s lifestyle, decision process, and technology 
utilization.29,32  
In this study, the ACE Measure was used to measure engagement levels in participants 
before and after undergoing a genetic counseling appointment. Participants were comprised of 
patients referred to the UPMC Hereditary Gastrointestinal (GI) Tumor Program for hereditary 
cancer risk assessment based on personal cancer diagnoses, and/or on having a family history of 
cancer. In addition, this pilot study aimed to assess the feasibility of implementing the ACE as a 
patient engagement measure in the clinic, as well as to evaluate patient recruitment methods, 
retention, and data analysis approaches for future research studies. 
3.2 METHODS 
3.2.1 Participants 
Participants were comprised of individuals seen at the University of Pittsburgh Medical Center 
(UPMC) Hereditary GI Tumor Program for genetic counseling. Participants were considered to 
be at an increased risk for a genetic cancer susceptibility based on an individual cancer history, 
or on a family history of cancer. Approval for the analysis was obtained from the University of 
Pittsburgh Institutional Review Boards (PRO16050209, 07/12/16) (Appendix C). 
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3.2.2 Eligibility Criteria 
Participants with a young age of cancer diagnosis, a rare cancer, multiple cancers, or suggestive 
tumor studies were all candidates for genetic counseling. Additionally, participants who reported 
several family members with cancer, especially first-degree relatives, rare or multiple cancers, 
and correlated cancers, were also candidates for genetic counseling and were evaluated for a 
genetic cancer susceptibility. 
3.2.3 Recruitment 
Participants were approached about the study at the beginning of their genetics appointment. For 
those participants who expressed interest in enrolling in the study, a research investigator 
provided informed consent, reviewed the consent form, and answered any questions prior to the 
genetic counseling appointment.  
3.2.4 Instrument 
Valid assessment measures are difficult to maintain in the rapidly advancing technology and 
changing standards of healthcare, and understanding patient engagement requires a 
comprehensive examination of factors such as a patient’s risk perception, skill set, confidence, 
and experience within the healthcare system.29  The majority of engagement measurement tools 
however, typically measure only one aspect of engagement, such as autonomy, resource 
preferences, or the decision making process. Other tools cover multiple domains of engagement, 
but are specific to management of a particular disease. 25,29,32  
The Altarum Consumer Engagement (ACE) Measure™ was created to address some of 
the limitations in current engagement measurement tools. The validity of the ACE Measure was 
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established in a study in which over 2,000 participant results were compared between the novel 
ACE Measure and the Patient Activation Measure (PAM), a tool used for patient activation 
analysis since 2006. The ACE Measure was confirmed to have significant statistical relevance 
and validity across three independent domains of health, as a holistic measure of patient 
engagement.29  
The ACE measure was created with the purpose of expanding the way in which patient 
engagement is measured and understood, as well as to incorporate modern information sources 
and technology available to patients. ACE can provide valuable information about necessary 
improvements within the system, but also can enable medical professionals to help patients 
become more confident and involved in their own health through the identification of strengths 
and weaknesses in their Commitment, Informed Choice, and Navigation scores. As such, the 
ACE can also be useful for medical professionals to evaluate the abilities of patients in making 
decisions, and the type and quantity of support that may be needed for each patient.32 
The ACE measure is a tool designed to evaluate the engagement of individuals in their 
healthcare. The ACE measure used for this study involves 12 questions, which evaluate three 
domains of health: Commitment, Navigation, and Informed Choice. The Commitment domain 
refers to an individual’s consistency and self-care habits. The Navigation domain captures an 
individual’s ability to communicate with healthcare providers. The Informed Choice domain 
































Figure 1. ACE Measure Domains 
 
In addition, the combination of the three domains, the total ACE score, reflects an 
individual’s average engagement in their health and general participation in the healthcare 
system. While the total ACE score acts as a reflection of a patient’s overall engagement level, the 
three domains provide more specific strengths and weaknesses for targeted interventions.  
3.2.5 ACE Measure Scoring 
The ACE Measure is composed of 12 questions across three health domains. For each of the 
domains (Commitment, Navigation, and Informed Choice) there are four related questions which 
are ranked on a Likert scale of “strongly disagree” to “strongly agree” (Appendix A). The 
answers were scored with “strongly disagree” being marked as zero points, and “strongly agree” 
being marked as four points. The four scores within each domain were then averaged and 
multiplied by 6.25 to provide a final score from 0 to 25 for each domain and ranked (Figure 2).32  
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Figure 2. ACE Measure Score Interpretation 
 
These three final scores for each domain can be summed to determine a person’s overall 
engagement score out of a total possible 75 points, which reflects a person’s average activation 
level in their health and within the healthcare system overall. 
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3.2.6 Procedures 
The research investigators overseeing the study included a gastroenterologist, genetic counselors, 
and a genetic counseling student who facilitated the study enrollment and follow-up 
questionnaire (Figure 3).  
Patients who provided informed consent were provided with the Altarum Consumer 
Engagement (ACE) Measure to assess their engagement level. The ACE was provided in written 
format, and completed by the participant in private. The form was collected by a research 
investigator prior to the genetic counseling session and the physician consult. During the 
appointment, participants underwent individualized genetic counseling, as well as a physician 
consult to review overall health.  
The genetic counseling intervention comprised a one-hour appointment in which patients 
received genetic education and information pertaining to hereditary cancer syndromes, and were 
engaged in personalized cancer risk assessment and psychosocial counseling. Visual aids were 
utilized to support patient comprehension. Participants were also provided with a written letter of 
summary after the appointment. Individuals who underwent genetic testing received a phone call 
for result disclosure and follow-up.   
Participants were then contacted three to five months after their office appointment via 
telephone and were asked the original 12 ACE Measure questions again.  
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Figure 3. Protocol Flowsheet 
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3.2.7 Data Analysis 
The ACE data were assessed for normality of distribution within each domain of health, and 
across the total ACE score (summation of domain scores). Data were assessed for distribution 
between patients recently diagnosed with cancer and those with a past personal or family history 
of cancer. Paired sample t-tests were utilized to determine mean differences in scores between 
pre and post genetic counseling across all participants (Appendix B). The statistical computer 
program STATA (StataCorp 2015)48 was used for the purpose of analysis and a significance 
threshold of p<0.05 was applied (95% Confidence Interval).  
3.3 RESULTS 
A total of 46 participants were recruited between July 2016 and October 2016, and each was 
followed for a period of at least three months after enrollment. Five participants were lost-to-
follow up, and two individuals passed away prior to the collection of the post-engagement level. 
Additionally, participants who failed to answer at least two questions in either of the Pre or Post 
ACE Measures were not included in the data analysis (1 individual). A final group of 38 
participants was included for analysis (Table 1). Nineteen participants had a recent diagnosis of 
cancer, with the majority of individuals undergoing treatment for colorectal cancer. A total of 
nineteen participants were referred for past personal history or a family history of cancer. Of 
these, twelve participants had never been diagnosed with cancer, while seven had a past personal 
cancer diagnosed greater than three years prior to enrollment and/or were no longer undergoing 
treatment (Appendix A). 
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3.3.1 Demographics  
Of the participants enrolled, 66% were female, and the majority were Caucasian (89%, n=34). 
Participant ranged in age from 18 years to 81 years (mean age of 53 years) and the majority of 
patients were in their 60s at the time of enrollment. Patients recently diagnosed with cancer 
comprised 50% of the sample population, with colorectal cancer being the most common 
diagnosis (Table 1).  
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Table 1. Participant Demographic Data 
  Gender Age Ethnicity Cancer Type (Age at Diagnosis) Current Cancer Family History of Cancer 
1 F 77 Caucasian Colon (dx. 77) Yes Yes 
2 M 61 Caucasian Colon (dx. 61) Yes Yes 
3 F 42 Caucasian Colon (dx. 42)  Yes Yes 
4 F 77 Caucasian Colon (dx. 77) Yes Yes 
5 F 49 Caucasian Colon (dx. 49), Soft tissue sarcoma (dx. 34) Yes Yes 
6 F 33 Caucasian Colon (dx. 33) Yes Yes 
7 M 48 Caucasian Colon (dx. 47) Yes Yes 
8 M 55 African American Colon (dx. 55) Yes Yes (Polyposis)  
9 F 42 Caucasian Colon (dx. 40) In treatment Yes 
10 F 81 Caucasian Colon (dx. 80)  Yes Yes 
11 F 49 Caucasian Rectal (dx. 48) Yes Yes 
12 F 64 Caucasian Pancreatic (dx. 62 mets) In treatment Yes 
13 M 65 Caucasian Pancreatic (dx. 63), Prostate (dx. 55)  Yes Yes 
14 F 60 African American Pancreatic (dx. 58) In treatment Yes 
15 F 60 Caucasian Bladder (dx. 60), Thyroid (dx. 39) Yes Yes 
16 F 39 African American Gastric (dx. 38) Yes Yes 
17 F 55 Caucasian Bile Duct (dx. 54) Yes Yes 
18 F 74 Caucasian Endometrial (dx. 71) In treatment Yes 
19 F 55 Caucasian Breast (dx. 52)  In treatment Yes (ATM mutation) 
20 F 67 Caucasian Colon (dx. 49) No Yes (HNPCC)* 
21 F 50 Caucasian Colon (dx. 46) No Yes 
22 F 41 Caucasian Thyroid (dx. 28) No Yes 
23 M 71 Caucasian Rectal (dx. 61) No Yes 
24 F 38 Caucasian Colon (dx.35) No Yes 
25 M 58 Caucasian Colon (dx. 38) No Yes 
26 M 71 Caucasian BCC No Yes 
27 M 18 African American None N/A Yes (Lynch Syndrome) 
28 M 50 Caucasian None N/A Yes (Lynch Syndrome) 
29 F 60 Caucasian None N/A Yes (Lynch Syndrome) 
30 M 47 Caucasian None N/A Yes (BRCA2 mutation*) 
31 F 64 Caucasian None N/A Yes (FAMMM*) 
32 F 49 Caucasian None N/A Yes 
33 F 32 Caucasian None N/A Yes 
34 M 61 Caucasian None N/A Yes 
35 F 31 Caucasian None N/A Yes 
36 M 30 Caucasian None N/A Yes 
37 M 30 Caucasian None N/A Yes 
38 F 75 Caucasian None N/A Yes 
*HNPCC: Hereditary Non-Polyposis Colorectal Cancer/ FAMMM: Familial Atypical Multiple Mole Melanoma 
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3.3.2 ACE Measure across all Participants 
Across all 38 participants, post ACE scores were higher following genetic counseling, indicating 
an increase in patient engagement after undergoing genetic counseling. The difference between 
pre and post ACE scores was statistically significant (two-sided p-value: Pr(|T| > |t|) = 0.0342) 
with a mean difference of approximately three points. The individual categories within the ACE 
Measure (Commitment, Navigation, and Informed Choice) were not found to have statistically 
significant changes (Pr(|T| > |t|) = 0.2049; Pr(|T| > |t|) = 0.0635; Pr(|T| > |t|) = 0.3025 
respectively). The Navigation domain however, was the domain with the largest change seen 
between pre and post scores overall. Navigation scores were seen to increase in the post ACE 
Measure by approximately one point on average (one-sided p-value: Pr(T < t) = 0.0318) 
(Appendix B). 
The majority of participants had either improved or maintained scores. For the data 
analysis, scores were analyzed based on the difference of the raw value scores (Table 2).  
 
Table 2. Participants Raw Data Scores 
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Further data analysis showed a moderately strong, positive correlation between pre and 
post scores across all three domains and in the total ACE scores (Tables 4-7). The pre and post 
scores for each domain were analyzed and the statistical relationship was described by the 
coefficient of determination (r-squared value). The Commitment domain was found to have a r-
squared value of 0.3385 (correlation coefficient r =0.5818). The Navigation domain’s r-squared 
value was 0.1606 (correlation coefficient r =0.4007), and the Informed Choice domain was 
0.4866 (correlation coefficient r =0.6976). The total ACE score coefficient of determination was 
r-squared= 0.4770 (correlation coefficient r =0.6907). 
In addition, the ACE Measure clusters scores into categories (lowest, below average, 
average, above average, or highest engagement scores) to better account for natural variation in 
scores over time. This means that while an individual’s overall score can change by one or two 
points, they may still be within range of their original category (Appendix B.1.1). For the 
purposes of this study, we looked at the differences in the raw scores independent of the 
categories to determine overall change and total engagement score differences. Analysis of both 
the raw score changes and category ranges however, support that the majority of participants 
either maintained or increased their scores, while the fewest number of participants had worse 




Table 3. Pre-Commitment vs. Post-Commitment ACE Scores 
 
r-squared value: 0.3385 
Table 4. Pre-Navigation vs. Post-Navigation ACE Scores 
 
r-squared value: 0.1606 
Table 5. Pre-Informed Choice vs. Post-Informed Choice ACE Scores 
 
r-squared value: 0.4866 




3.3.3 ACE Measure between Recent Cancer Diagnosis and Family History  
There were no statistically significant differences found between patients who had recent cancer 
diagnoses and those who were primarily referred for past personal history or family history of 
cancers in any categories of the ACE Measure. The total pre and post ACE scores were 
determined by two-sample, unpaired t test with equal variance, and no difference was found 
between the two groups (Pr(|T| > |t|) = 0.2042). The three categories within the ACE Measures 
did not indicate statistically significant differences between the two populations (Commitment 
Pr(|T| > |t|) = 0.6732; Navigation Pr(|T| > |t|) = 0.1795; Informed Choice Pr(|T| > |t|) = 0.5062). 
The Navigation domain however, was found to have the largest difference between populations. 
Participants with a past personal history or family history of cancer had a larger change in the 
Navigation Domain than those with a recent cancer diagnosis (one-sided p-value: Pr(T < t) = 
0.0897) (Appendix B). 
3.3.4 ACE Measure between Male and Female Participants 
The ACE Measure scores observed between male and female participants were also analyzed.  
Across each of the ACE Measure domains, there was no statistically significant differences in 
the commitment levels observed in either gender (Commitment Pr(|T| > |t|) = 0.1851; Navigation 
Pr(|T| > |t|) = 0.3094; Informed Choice Pr(|T| > |t|) = 0.7813). The combined total scores for the 
ACE Measure in both women and men were not statistically significant for differences in patient 
engagement changes between the sexes ((Pr(|T| > |t|) = 0.1842) (Appendix B). 
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3.3.5 Pre and Post ACE Measure Changes by Participant Age 
The majority of participants were between the ages of 30s and 70s years of age. However, there 
was one participant who was 18 years of age and one who was 81 years of age. The mean value 
of pre and post ACE score changes were analyzed by age in decades. Those patients in their 40s 
were observed to have the most significant change from pre to post score, with a mean increase 
of 6.055 points. Those in their 60s were closest to the overall average difference in scores, with a 
mean change of 3.530 points. Those in their 30s and 70s were seen to have the lowest overall 
changes in scores, with an increase in scores by approximately 0.24 points. Interestingly, the 
youngest participant was seen to have the largest change in engagement scores (difference of 
7.813), while the oldest participant had an overall decrease in engagement score (difference of -
3.125) (Appendix B). 
3.4 DISCUSSION 
In response to the Affordable Care Act (ACA 2010), patient outcomes are now required quality 
measures for specific healthcare institutions.38 Such practices underscore the need for both valid 
measure tools, as well as improved means of engaging patients in their health.37 
In this study, genetic counseling was found to have a positive impact on patient 
engagement over time. Previous research on genetic counseling outcomes has identified several 
patient benefits. Meta-analysis reviews of the literature found that genetic counseling can lead to 
improved patient understanding of cancer risks, complex disease, and are also more likely to 
adhere to medical management, such as participation in cancer screening.45,46 Additionally, 
previous research in genetic counseling outcomes described enhanced psychological adaptation 
to genetic information, as well as increased patient empowerment.41,42,44–46  
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Genetic counseling was associated with increased total ACE scores, indicating that 
genetic counseling may also contribute to increased patient engagement. Changes in scores 
across all participants, regardless of cancer diagnosis, were statistically significant, and may 
suggest a clinically meaningful intervention.  
The ability to measure patient engagement outcomes is essential, yet measurement tools 
are limited. The ACE Measure (2015) was developed with the intention to better capture patient 
engagement in a holistic manner, and has since been used to determine engagement levels over 
time and to predict outcomes in diabetic patients at the University of California, Los Angles 
(UCLA). When measured in six month intervals, ACE scores have been observed to have fairly 
stable consistency, with moderate positive correlation over time (correlation coefficient r =0.6) 
(unpublished data, UCLA). The data reported in ACE scores among cancer patients for this study 
also found a correlation coefficient of approximately r =0.6 across the Commitment, Informed 
Choice, and total ACE scores as well in the observed three months.  
The individual ACE domains were also used to correlate patient outcomes in diabetic 
individuals. In the diabetic population, the Commitment Domain was able to predict 
improvement or decline in glycated hemoglobin (HbA1c) levels over time (unpublished data, 
UCLA). While individual ACE domains were not found to have statistically significant changes 
in cancer patients for this study, the Navigation Domain was observed to have the largest 
difference amongst all participants. The Navigation Domain is associated with an individual’s 
comfort level in asking questions of their healthcare providers, as well as providing feedback 
about their experiences and expectations for the type of care they will receive. The near-
significant increase in Navigation scores may reflect the success of genetic counseling in 
empowering patients to engage in discussion about their health, and in establishing an 
environment that allowed for patients to reflect and provide feedback about their healthcare 
management, ultimately driving increased patient empowerment.37   
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In addition, participants who underwent genetic counseling based on a family history of 
cancers had a larger change in their Navigation score than those patients with a recent cancer 
diagnosis, although the observation was not statistically significant. A possible explanation for 
this observed difference could be as a result of each group’s goal in undergoing genetic 
counseling. While a cancer patient may be most interested in next steps and treatment options, an 
individual referred on the basis of family history may have a broader agenda, leading to more 
questions and interest in generalized knowledge seeking related to hereditary cancer. Genetic 
counselors are specialists trained in engaging patients in bi-directional, active communication, 
with a focus on building rapport.41 The difference in perspective of these two groups of 
participants, their current immersion in the healthcare system, as well as the focus of the genetic 
counseling discussion, could explain the observed changes in the Navigation scores between 
these two groups.  
 Scores for the three ACE domains are independently validated, but the ability to measure 
the total score change and to assign statistical significance was restricted by the classification of 
engagement levels. Paired sample t-test analysis of the mean difference in total scores therefore, 
was an approach that was better able to determine statistically significant changes in patient 
engagement levels both across domains, and in overall scores.  
The classification of scores into engagement levels (below average, average, above 
average, etc.) also limited interpretation as a result of the range variation between categories. The 
ACE classification category ranges may be as wide as 12 points (Lowest score (0-12.5); 
Commitment and Navigation Domains) or as narrow as one point (Above Average score (18-19); 
Navigation Domain), which can significantly influence a participants’ status as “changed” vs. 
“maintained” engagement. Due to this score classification range the t-test analysis determined 
that more participants improved, rather than maintained, engagement scores based on the mean 
difference of the scores. The classification of scores by range and the analysis performed by 
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mean score difference however, both support the conclusion that there were more participants 
with improved scores than with worsened scores, and that the Navigation Domain reflected the 
largest score changes across all participants. 
 Difference in engagement across genders and ages were also analyzed. No changes were 
found between engagement levels in males and females. Previous research has found that men 
have worse health seeking behaviors than women, and are less likely to engage in screening and 
health management.49–52 Such results could be a consequence of an insufficient sample size, a 
biased sample population, or may reflect the personalized approach of trained genetic counselors 
to target information to patient needs.52  
With regards to age, the greatest changes in pre and post scores on average, were 
observed in individuals in their 40s, followed by individuals in their 60s. The lowest observed 
changes were reported in participants in their 30s and 70s. However, no statistically significant 
analysis was determined for age related engagement.  
To our knowledge, this is the first utilization of the ACE Measure to determine changes 
in patient engagement outcomes for genetic counseling in a specialty cancer clinic setting. The 
purpose of this pilot study was to analyze how patient engagement levels changed after 
undergoing genetic counseling and to determine the feasibility of long-term implementation of 
the ACE Measure in a specialty clinic.  The results observed in this study support the utility of 
the described methodology for measuring patient engagement and defining a genetic counseling 
outcome. In addition, the data suggests preliminary trends, such as increased engagement post 
genetic counseling, and age related engagement levels that merit further evaluation.   
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3.4.1 Research Recommendations and Limitations 
The preliminary results discussed in this study merit further investigation. Additional research on 
large populations in the clinical setting may provide more evidence regarding the impact of 
genetic counseling on patient engagement, as well as determine risk stratification and 
personalized approaches to individuals identified at lower levels of engagement. As an 
observational pilot study, this research also lacked a control group, so changes in engagement 
cannot be definitely attribute to genetic counseling alone. 
One limitation in this research is the difference in data collection methods through an in-
person written survey, and a three-month thereafter telephone survey. The “social desirability” 
bias refers to the phenomenon that participants may report perceived desirable traits rather than 
true, but socially undesirable, traits.53 While there is some evidence to suggest that such bias is 
more frequent during person-based interactions, such as telephone interviews, the total impact of 
the bias is uncertain.53 While this study strove to minimize bias through inclusion of normalizing 
dialect, such bias cannot be disregarded.  
Further investigation of patient engagement on additional health outcomes may also be an 
avenue of research. The role of patient engagement on lifestyle factors, such as weight loss and 
tobacco cessation, which are factors established in reducing cancer risk, may indicate larger 
public health interventions to reduce long-term healthcare costs. Although the data are not 
shown, additional analysis of the correlation between engagement and short term success in 
weight loss and tobacco cessation has been performed, and determined that initial ACE scores 
can be predictive of successful behavior modifications over time. Identification of successful 
interventions, such as genetic counseling or personal health coaching, that increase patient 
engagement should be studied for their impact on lifestyle changes and on public health. 
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3.5 CONCLUSION 
Patient engagement within the healthcare system can have major implications for individual 
health outcomes, as well as on reduced healthcare costs. This study is the first known report of 
patient engagement levels in individuals undergoing genetic counseling in a specialty cancer 
clinic. The differences seen in levels of engagement were found to be statistically significant 
regardless of an individual diagnosis of cancer, suggesting that genetic counseling may empower 
patients to have lasting involvement in their health and in the health care system. Preliminary 
results reflect the value of the services provided by genetic counselors, and the significance of 
their availability in the clinic setting. Additional investigation of patient empowerment over time 
and across specialty settings has been confirmed to be both feasible and warranted through this 
pilot study.  
4.0  RESEARCH SIGNIFICANCE TO GENETIC COUNSELING AND PUBLIC 
HEALTH 
The purpose of this pilot study was to analyze the impact of genetic counseling on patient 
engagement and to determine the feasibility of implementation in healthcare practice. This 
research is of particular importance to the field of genetic counseling and public health. Patient 
engagement has long been a suspected outcome of genetic counseling, as genetic counselors are 
trained in psychosocial interventions, bi-directional communication, and personalized 
information delivery.42 Previous research has found that genetic counseling can increase patient 
satisfaction and understanding, as well as promote patient empowerment over time.42,45,54  
Research on the impact of patient engagement in their health and genetic counseling 
however, is limited. Such research is fundamental in underscoring the value of genetic 
counselors in the clinic, and in targeting approach modifications and areas of improvement. The 
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preliminary results of this study suggest that genetic counseling is not only a valuable component 
of the healthcare system because of increased patient understanding and satisfaction, but also in 
improving patient engagement in their health. This has implications for public health on a whole, 
as improved engagement in populations can lead to overall better quality of life.  
Patient engagement has been linked to a range of beneficial outcomes not only for 
patients, but for healthcare organizations as well. Patients who were found to have high 
engagement levels reported higher satisfaction with their healthcare, and are even seen to recover 
faster from illnesses. High levels of engagement were also correlated with improved medical 
adherence, shorter lengths of stay in hospitals, and better long term quality of life. Additionally, 
patients who are considered to be highly engaged in their health and in the medical system have 
half the rate of medical errors compared to those with low-levels of participation.29 
From the provider’s perspective, patient engagement has been shown to afford significant 
cost reduction in healthcare. When patients are engaged in their health, finances and resources 
are preserved through the avoidance of unnecessary surgeries, better adherence to medical 
management, and the prevention medical errors. Patient participation can also reduce healthcare 
costs by choosing options based on an individual’s preference, rather than simply being provided 
with the standard of care approach.25 High levels of patient involvement lead to safer, more 
effective, and less expensive healthcare overall. As such, the active role of patients in managing 
their health is important to increase satisfaction and successful outcomes, and to develop 
economically sustainable healthcare systems. 
Patient engagement research is also important to the field of public health, as it can allow 
for the identification of targeted populations, segmentation, and evaluation of existing 
interventions. Participation rates can also provide key information about risk stratification for 
targeted interventions, help to facilitate customized care pathways, and provide enhanced care 
both at an individual and community level.25 Patient engagement measures can provide 
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information to guide physician intervention through the identification of patient strengths and 
weaknesses, and providing appropriate support and referrals for customized care. Additionally, 
engagement measures can identify subsets of patients that could benefit from targeted 
interventions to facilitate increased engagement at a population level.  
Although this pilot study has identified statistically significant correlations, the small 
study size and short timeframe indicate the data may not yet imply clinical changes, but rather 
suggest initial trends for additional research. The preliminary results discussed in this study merit 
further investigation. One such avenue of research may be on the association between patient 
engagement and health outcomes. The role of patient engagement on lifestyle factors, such as 
weight loss and tobacco cessation, may be able to identify larger public health interventions, with 
the potential to reduce long-term healthcare costs. Preliminary data on such associations are 
included in the Public Health Chapter of this thesis, and found that initial ACE scores can be 
predictive of successful and unsuccessful behavior modifications over time. Identification of 
successful interventions, such as genetic counseling or personal health coaching, that increase 
patient engagement should be studied for their impact on lifestyle changes and on public health, 
both in a larger sample population and over an extended period of time to determine novel 
interventions for the benefit of patients and public health endeavors.  
5.0  PUBLIC HEALTH ESSAY 
5.1 INTRODUCTION 
Public Health is defined as the actions taken to protect and improve the health of communities 
through the detection and control of disease, research for disease prevention, and the promotion 
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of healthy lifestyles.55 Patient engagement is imperative to public health as it captures the 
abilities and activities of individuals in the community in regards to their health management. 
Patients with higher levels of engagement are less likely to require multiple hospital visits for 
chronic illnesses, recover faster from illness, and have higher satisfaction in the healthcare 
system.25 While patient engagement is targeted at the individual level, the impact of increased 
healthcare engagement has population effects and the potential to influence public health on a 
larger scale.  
This pilot study addressed the question of whether genetic counseling can empower 
patients to become more involved in their health and the healthcare system. While preliminary 
trends found that patient engagement does increase following genetic counseling, more research 
about behavior changes is needed. Therefore, in addition to tracking the ACE Measure for 
participants over a period of three months, this study also analyzed additional lifestyle factors 
through phone questionnaires that tracked behavior change in patients post-genetic counseling. 
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5.2 PARTICIPANTS 
The total number of participants in this pilot study included 38 individuals. In order to analyze 
lifestyle changes, a subset of these participants were asked additional questions regarding their 
health and habits. Participants seen for genetic counseling who were also current smokers, or 
whose BMI was greater than 30 kg/m2, completed a lifestyle questionnaire (Appendix A) via 
telephone three months post-genetic counseling at the same time as they were called for the ACE 
Measure post-survey (Figure 4). If an individual was both a current smoker and had a BMI 
greater than 30 kg/m2, the physician and patient worked together to determine the lifestyle 
change that was most important to them (in both cases, each participant selected to address 
tobacco cessation). Of the 38 individuals, 13 participants met criteria for weight loss or tobacco 
usage. Seven of the thirteen participants were recently diagnosed with cancer, and the remaining 
six participants were seen for a family history of cancer. 
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Figure 4. Lifestyle Behavior Protocol Flowsheet 
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5.3 RESULTS 
Participants were asked several questions concerning their perceived ability to maintain a healthy 
lifestyle, as well as asked to report on their most recent weight and smoking status. Participants 
who reported a higher weight or no change in weight were categorized as “failure to change.” 
Likewise, those participants who were not in a current quit attempt were considered as “failure to 
change” behavior status. Participants who either reported a lower weight, or were currently in a 
quit-attempt, were noted as “successful in change” status.   
Seven participants were recently diagnosed with cancer, of which 86% (n=6) failed to 
change their lifestyle behaviors. However, of those participants who were seen for family history 
of cancer, 83% (n=5) were successful in changing their lifestyle behaviors. The majority of 
successful changes took place in individuals who were not recently diagnosed with cancer, 
demonstrating a potential target group for intervention.  
 







A total of six participants were observed for tobacco cessation, and a total of seven participants 
were observed for weight loss behaviors. The average weight loss observed was approximately 
three pounds. Of the participants who reported being in a current quit-attempt, one had not 
smoked in over two months, while the other two participants reported utilization of medication 
for the quit attempt and a period of non-smoking average of five days. In each group, the ratio of 






Diagnosis 6 1 7 
Family History of 
Cancer 1 5 6 
Tobacco Lifestyle 3 3 6 
Weight Loss 
Lifestyle 4 3 7 
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participants who failed to change versus participants who succeed in change was approximately 
50:50. (Table 4)  
 






Participants who failed to change their behavior had an overall lower Pre-ACE Measure score 
compared to those who were successful in change (mean difference of 4.7 points). The average 
total Post-ACE scores for both groups however, were similar, indicating a larger positive change 
in those who failed to change their lifestyle behaviors (mean difference of 1.9 points). (Table 5). 
This trend may indicate that the initial pre-ACE engagement score is more informative regarding 
whether an individual will change lifestyle factors.  
Table 9. Failed Change and Successful Change ACE Domains Summary  
 
Participants who failed to change their lifestyle had a greater overall increase in their 
commitment scores (mean difference of +2.46 points) compared to those who were successful in 




Total score 46.7 51.3 4.7 
Mean Post-ACE 
Total score 51.2 53.1 1.9 
DIFFERENCE 4.6 1.8 
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change (mean difference of +0.26 points). The Navigation domain was observed to have a larger 
change among those who were successful in change (mean difference of +2.17 points) as 
compared to those who failed to change (mean difference of -0.45) (Table 6). The differences 
observed in the Navigation scores observed however, were not statistically significant (one-sided 
p-value: Pr(T < t) = 0.0914). (Appendix D) 
In the Informed Choice domain however, statistically significant differences were 
observed. Patients who failed to change their weight or smoking habits had an overall increased 
score in the Informed Choice domain than those who were successful (two-sided p-value: Pr(|T| 
> |t|) = 0.0058). Among participants who were successful in change, the mean difference in 
Informed Choice score was decreased (mean difference of -0.52 points), compared to those who 
failed to change (mean difference of +2.68 points). However, both the mean pre and post ACE 
scores in successful change individuals were higher than mean post ACE score among failure to 
change participants. The difference in the informed choice domain was the most significantly 
increase change observed across all domains in both participants who failed to change and those 
who were successful in change.  
5.4 DISCUSSION 
While lifestyle behaviors have been shown to reduce cancer risk in the general population, fewer 
studies are available that analyze the effect of behavior on hereditary cancers. Hereditary 
cancers, such as Hereditary Breast and Ovarian (HBOC) and Lynch syndrome, have an increased 
risk for the development of specific cancers. For the HBOC genes, the risk for breast cancer in a 
woman’s lifetime may be as high as 70%, whereas Lynch-related gene mutations confer a risk 
for colorectal cancer that may be as high as 69%.14,16 While these risks are significantly 
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increased compared the general population, they are not 100%. Due to the difference in 
penetrance and cancer incidence between individuals, even within the same family, researchers 
suggested that risk-modifying factors contribute to cancer development.16–18 
Previous investigators have reported that such lifestyle factors can include obesity and 
tobacco usage. The incidence of hereditary breast cancer was lower among individuals who 
report high levels of physical activity, while a diet high in fruit and vegetables has been shown to 
reduce cancer risk in individuals with Lynch syndrome.20–22 Similarly, smoking has been 
associated with higher overall cancer development rates in both the general population, as well 
as in individuals with hereditary cancer predispositions.23 
While studies suggest that behavior can influence cancer development even in individuals 
with a hereditary predisposition, the likelihood of lifestyle mediation can be dependent on cancer 
status. One study observed lifestyle behaviors among individuals at risk for Lynch syndrome. 
The study of over four hundred participants looked at both individuals who had a colorectal 
cancer diagnosis and unaffected, at-risk relatives. The investigators reported that individuals who 
had not had a previous cancer diagnosis were more likely to have poor lifestyle behaviors, such 
as poor diet and/or smoking, compared to individuals previously been diagnosed with cancer, 
despite all participants being at risk for a hereditary cancer predisposition.24  
In our research however, we found that the majority of successful lifestyle changes took 
place among individuals who were referred on the basis of family history, and that those with a 
recent cancer diagnosis were less likely to change lifestyle. Of note however, two of the 
participants seen for family history had a previous colon cancer diagnosis (diagnosed over three 
years prior to enrollment with completion of treatment) (Appendix A). One possible explanation 
for this observed difference may be due to an individual’s goal in undergoing genetic counseling. 
While a cancer patient may be most interested in next steps and treatment options, an individual 
referred on the basis of family history may have a broader agenda, leading to more questions and 
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seeking generalized knowledge. Also, it is reasonable to speculate that participants recently 
diagnosed with cancer would prioritize completing treatment and getting well before undergoing 
lifestyle modifications to reduce future, secondary cancer risk.  
Another possible explanation for the observed results regards the constraints of the study 
timeline. Participants were followed for a period of three months. While this time frame allows 
for lifestyle changes to be made, it may not be sufficient time for commitment scores to adjust to 
new lifestyle habits and consistent, improved levels. The structure of this research as a pilot 
study limits both the sample size and the ability to follow participants for an extended period of 
time, however, the trends observed in analysis lay the foundation for further research.56  
In the design of the ACE Measure, the domain most suited to determine changes in 
lifestyle in individuals is the Commitment Domain. This domain reflects participants’ habits and 
self-care consistency over time. There were however, no significant differences observed in 
those who failed to change and those who were successful in change for the Commitment 
Domain. In fact, the data interpretation determined that the Informed Choice domain had 
statistically significant differences between participants who were successful and those who were 
not. The Informed Choice domain encompasses the types of resources that are used when an 
individual makes health decisions (i.e.: online resources, official medical rankings, etc.). While 
the Informed Choice domain aims to capture resources used to select healthcare providers, it 
does not uncover types of resources patients seek when making lifestyle changes. The 
statistically significant change in the Informed Choice scores between these populations (in 
which those who do not change their lifestyles had a larger change) may suggest that the use of 
online resources to select healthcare providers has little contribution to the ability to modify 
lifestyle behaviors. However, the mean pre and post Informed Choice Score was higher overall 
in those individuals who were successful in change, which may suggest a threshold value for 
change.  
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For the Navigation domain however, the difference in mean scores for those who failed 
to change decreased, while those who were successful in change had the greatest increase in 
scores, and also had higher pre and post ACE mean scores. The Navigation Domain is correlated 
with the comfort of an individual to engage their health care providers, in asking questions, and 
in relaying their experiences in the healthcare system. The increase in Navigation scores 
observed among those who were successful in change due to having a successful experience 
(losing weight/quitting smoking) and were therefore more empowered and engaged in their own 
health at the time of the questionnaire. The empowerment of success is an important aspect of 
the feedback loop that drives the patient engagement as a healthcare endeavor.57 This result 
could suggest that having a successful experience in changing behaviors may result in higher 
comfort in communication with healthcare providers.  
Furthermore, our study determined that individuals with a higher initial ACE score were 
more likely to be successful in their lifestyle change. Another, current study has also used the 
ACE Measure to correlated patient outcomes with improved or declined glycated hemoglobin 
(HbA1c) levels in diabetic patients over time (unpublished data). The study found that the 
Commitment Domain score was correlated with patient outcomes in diabetic patients. In this 
study however, the commitment domain by itself was not informative with regards to patient 
outcome. Rather, the total pre-ACE score was more informative in that lower scores were 
associated with failure to change, while higher scores were seen in those who were successful. 
At the time of the follow-up questionnaire however, the gap between the total ACE scores had 
decreased. Successful participants had a mean total ACE score difference of approximately +2 
points, whereas participants who failed to change had a difference in ACE scores by almost +5 
points.  As a result, the post-ACE score of those participants who failed to change was similar to 
the pre-ACE score of those participants who were successful. This result may suggest that if the 
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participants were observed for a longer period of time, more participants may have had positive 
lifestyle changes.  
Also, the observed data indicate that tobacco cessation and weight loss may be 
comparable lifestyles, and that the failure or success of an individual was not dependent on the 
lifestyle behavior they were asked to change. In the literature, long-term weight loss and tobacco 
cessation have about the same success rate as well (5% success in traditional weight loss method, 
and 4.5% success in cold turkey quit attempts).58,59 Successful change for both lifestyles is 
thought to increase with the usage of accredited program and support groups, as both lifestyle 
behaviors have similar addictive and psychological aspects that make change difficult. In this 
study, six participants were analyzed for smoking cessation, while seven were observed for 
weight loss. In each lifestyle group, approximately half failed to change and half succeeded in 
change. Considering the low success rate of both lifestyle factors, our report is significant in that 
despite low numbers, approximately half of participants were able to successfully change over a 
three-month period. This result may be due to a limited sample size, short time frame, and 
definition of success long-term, or it may indicate additional benefits of genetic counseling, but 
certainly merits further research consideration.  
5.5 CONCLUSION 
The participants in this study have either a family history of cancer or a personal diagnosis that 
may indicate a higher risk for cancer, and thus would benefit from lifestyle modifications to 
reduce risk. To our knowledge, this study is the first utilization of the ACE Measure to determine 
correlations between engagement scores and lifestyle behavior changes in a specialty cancer 
clinic setting. The results observed in this study support the feasibility of long-term 
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implementation of the ACE Measure for measuring patient engagement, as well as correlation to 
patient outcomes in lifestyle modification for tobacco cessation and weight loss. In addition, the 
data suggest preliminary trends, such as the possibility that increased engagement scores may 
predict successful lifestyle behavior change, that merit further evaluation. 
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APPENDIX A: DOCUMENTATION FOR METHODOLOGY 
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A.1 ACE MEASURE 
55 
A.2 ACE LICENSURE LETTER 
56    
57   
58   
59   
60   
61   
62   
63   
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A.3 PARTICIPANT DATA AND LIFESTYLE BEHAVIOR DOCUMENTS 
 Patient ID Age Gender Ethnicity BMI (kg/m2) Tobacco Use Cancer Type Current Cancer Family History 1 RXW006 77 F Caucasian 22.27 Never Colon (dx. 77) Yes Yes 
2 RXW010 61 M Caucasian 23.24 Current Colon (dx. 61) Yes Yes 
3 RXW016 42 F Caucasian 24.63 Never Colon (dx. 42) Yes Yes 
4 RXW026 77 F Caucasian 31.32 Never Colon (dx. 77) Yes Yes 
5 RXW033 49 F Caucasian 23.33 Former Colon (dx. 49), soft tissue sarcoma (dx. 34) Yes Yes 
6 RXW035 33 F Caucasian 32.61 Never Colon (dx. 33) Yes Yes 
7 RXW041 48 M Caucasian 26.05 Never Colon (dx. 47) Yes Yes 
8 RXW043 55 M African American 27.8 Current Colon (dx. 55) Yes Yes (Polyposis) 
9 RXW045 42 F Caucasian 28.25 Never Colon (dx. 40) Undergoing treatment Yes 
10 RXW051 81 F Caucasian 24.06 Never Colon (dx. 80) Yes Yes 
11 RXW037 49 F Caucasian 31.95 Current Rectal (dx. 48) Yes Yes 
12 RXW012 64 F Caucasian 22.67 Current Pancreatic (dx. 62 mets) Undergoing treatment Yes 
13 RXW036 65 M Caucasian 21.84 Former Pancreatic (dx. 63), Prostate (dx. 55) Yes Yes 
14 RXW044 60 F African American 26.43 Former Pancreatic (dx. 58) Undergoing treatment Yes 
15 RXW001 60 F Caucasian 21.56 Never Bladder (dx. 60), Thyroid (dx. 39) Yes Yes 
16 RXW015 39 F African American 18.3 Never Gastric (dx. 38) Yes Yes 
17 RXW019 55 F Caucasian 30.99 Never Bile Duct (dx. 54) Yes Yes 
18 RXW022 74 F Caucasian 22.94 Former Endometrial (dx. 71) Undergoing treatment Yes 
19 RXW031 55 F Caucasian 26.95 Never Breast (dx. 52) Undergoing treatment Yes (ATM) 
20 RXW047 67 F Caucasian 24.51 Never Colon (dx. 49) No Yes (HNPCC) 
21 RXW005 50 F Caucasian 29.76 Former Colon (dx. 46) No Yes 
22 RXW014 41 F Caucasian 28.25 Former Thyroid (dx. 28) No Yes 
23 RXW017 71 M Caucasian 29.7 Former Rectal (dx. 61) No Yes 
24 RXW020 38 F Caucasian 33.64 Never Colon (dx.35) No Yes 
25 RXW021 58 M Caucasian 32.58 Never Colon (dx. 38) No Yes 
26 RXW038 71 M Caucasian 34.06 Former BCC No Yes 
27 RXW004 18 M African American 22.26 Never None . Yes (Lynch) 
28 RXW029 50 M Caucasian 22.96 Former None . Yes (Lynch) 
29 RXW052 60 F Caucasian 21.28 Former None . Yes (Lynch) 
30 RXW028 47 M Caucasian 22.78 Current None . Yes (BRCA2) 
31 RXW048 64 F Caucasian 25.54 Never None . Yes (FAMMM) 
32 RXW002 49 F Caucasian 20.47 Never None . Yes 
33 RXW003 32 F Caucasian 26.89 Never None . Yes 
34 RXW007 61 M Caucasian 37.93 Never None . Yes 
35 RXW011 31 F Caucasian 29.41 Never None . Yes 
36 RXW023 30 M Caucasian 28.37 Former None . Yes 
37 RXW024 30 M Caucasian 30.67 Current None . Yes 
38 RXW040 75 F Caucasian 19.01 Never None . Yes 
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A.4 CONSENT FORM 
68  
69 
A.5 IRB APPROVAL LETTER 
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APPENDIX B: DATA DISTRIBUTION AND STATA OUTPUT 
This appendix includes histogram graphs of data subsections and STATA program output 
analysis for T-test.  
71 
B.1 DATA ACROSS ALL PARTICIPANTS 
B.1.1 ACE Summary of Pre and Post Scores in Each Domain 
    
  
*Used with permission from UPMC Health Plan and Work Partners 2017 
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B.1.2 Commitment Pre and Post ACE Scores 
COMMITMENT PRE-ACE SCORES  
  
COMMITMENT POST-ACE SCORES 
  
 
STATA COMMITMENT PRE AND POST ACE SCORES OUTPUT 
Paired t test 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
Commit~e |      38    18.83242    .6794816    4.188606    17.45566    20.20918 
Commit~t |      38    19.57257    .5488351    3.383247    18.46052    20.68461 
---------+-------------------------------------------------------------------- 
    diff |      38   -.7401447     .573585    3.535816   -1.902338    .4220489 
------------------------------------------------------------------------------ 
     mean(diff) = mean(CommitmentPre - CommitmentPost)            t =  -1.2904 
 Ho: mean(diff) = 0                              degrees of freedom =       37 
 
 Ha: mean(diff) < 0           Ha: mean(diff) != 0           Ha: mean(diff) > 0 
 Pr(T < t) = 0.1025         Pr(|T| > |t|) = 0.2049          Pr(T > t) = 0.8975 
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B.1.3 Navigation Pre and Post ACE Scores  
NAVIGATION PRE-ACE SCORES 
 




STATA NAVIGATION PRE AND POST ACE SCORES OUTPUT 
Paired t test 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
Naviga~e |      38    18.44871    .5688585    3.506679    17.29609    19.60133 
Naviga~t |      38    19.57259    .4991299    3.076843    18.56126    20.58393 
---------+-------------------------------------------------------------------- 
    diff |      38   -1.123882    .5875101    3.621655    -2.31429    .0665269 
------------------------------------------------------------------------------ 
     mean(diff) = mean(NavigationPre - NavigationPost)            t =  -1.9130 
 Ho: mean(diff) = 0                              degrees of freedom =       37 
  
 Ha: mean(diff) < 0           Ha: mean(diff) != 0           Ha: mean(diff) > 0 
 Pr(T < t) = 0.0318         Pr(|T| > |t|) = 0.0635          Pr(T > t) = 0.9682 
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B.1.4 Informed Choice Pre and Post ACE Scores  
INFORMED CHOICE PRE-ACE SCORES 
 




STATA INFORMED CHOICE PRE AND POST ACE SCORES OUTPUT 
Paired t test 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
Inform~e |      38    13.81596    .8651535    5.333164    12.06299    15.56893 
Inform~t |      38    14.51509    .8537957     5.26315    12.78514    16.24505 
---------+-------------------------------------------------------------------- 
    diff |      38   -.6991316    .6685388     4.12115    -2.05372    .6554568 
------------------------------------------------------------------------------ 
     mean(diff) = mean(InformedChoice~e - InformedChoice~t)       t =  -1.0458 
 Ho: mean(diff) = 0                              degrees of freedom =       37 
 
 Ha: mean(diff) < 0           Ha: mean(diff) != 0           Ha: mean(diff) > 0 
 Pr(T < t) = 0.1512         Pr(|T| > |t|) = 0.3025          Pr(T > t) = 0.8488 
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B.1.5 Total Pre and Post ACE Scores  
TOTAL PRE-ACE SCORES 
  




STATA TOTAL PRE AND POST ACE SCORES OUTPUT  
 
Paired t test 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
TotalPre |      38    51.09678    1.589156    9.796217    47.87684    54.31671 
TotalP~t |      38    53.65972    1.292818    7.969467    51.04022    56.27922 
---------+-------------------------------------------------------------------- 
    diff |      38   -2.562947    1.165682    7.185747   -4.924844   -.2010511 
------------------------------------------------------------------------------ 
     mean(diff) = mean(TotalPre - TotalPost)                      t =  -2.1987 
 Ho: mean(diff) = 0                              degrees of freedom =       37 
 
 Ha: mean(diff) < 0           Ha: mean(diff) != 0           Ha: mean(diff) > 0 
 Pr(T < t) = 0.0171         Pr(|T| > |t|) = 0.0342          Pr(T > t) = 0.9829
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B.2 DATA BETWEEN PARTICIPANTS WITH RECENT CANCER DIAGNOSIS 
AND PARTICIPANTS WITH FAMILY HISTORY 
B.2.1 Commitment Pre and Post ACE Scores  
COMMITMENT SCORE CHANGES IN PATIENTS WITH RECENT CANCER DIAGNOSIS 
 
COMMITMENT SCORE CHANGES IN PATIENTS WITH FAMILY HISTORIES OF CANCER 
 
STATA DIFFERENCES IN COMMITMENT SCORES BETWEEN PARTICIPANTS WITH CANCER AND 
PARTICIPANTS WITH FAMILY HISTORY OF CANCER OUTPUT 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
Com~rDif |      19    .4935263    .8785309    3.829428   -1.352199    2.339251 
Com~xDif |      19    .9868421    .7577569    3.302986    -.605146     2.57883 
---------+-------------------------------------------------------------------- 
combined |      38    .7401842    .5736311      3.5361   -.4221028    1.902471 
---------+-------------------------------------------------------------------- 
    diff |           -.4933158    1.160178               -2.846265    1.859633 
------------------------------------------------------------------------------ 
    diff = mean(CommitmentCanc~f) - mean(CommitmentFHxDif)        t =  -0.4252 
Ho: diff = 0                                     degrees of freedom =       36 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.3366         Pr(|T| > |t|) = 0.6732          Pr(T > t) = 0.6634 
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B.2.2 Navigation Pre and Post ACE Scores 
NAVIGATION SCORE CHANGES IN PATIENTS WITH RECENT CANCER DIAGNOSIS 
 
NAVIGATION SCORE CHANGES IN PATIENTS WITH FAMILY HISTORIES OF CANCER 
  
 
STATA DIFFERENCES IN NAVIGATION SCORES BETWEEN PARTICIPANTS WITH CANCER AND 
PARTICIPANTS WITH FAMILY HISTORY OF CANCER OUTPUT 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
Nav~rDif |      19    .3289474    .7978384    3.477697   -1.347249    2.005144 
Nav~xDif |      19    1.918947    .8440468    3.679115    .1456708    3.692224 
---------+-------------------------------------------------------------------- 
combined |      38    1.123947    .5875436    3.621862    -.066529    2.314424 
---------+-------------------------------------------------------------------- 
    diff |               -1.59    1.161448               -3.945526    .7655254 
------------------------------------------------------------------------------ 
    diff = mean(NavigationCanc~f) - mean(NavigationFHxDif)        t =  -1.3690 
Ho: diff = 0                                     degrees of freedom =       36 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.0897         Pr(|T| > |t|) = 0.1795          Pr(T > t) = 0.9103 
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B.2.3 Informed Choice Pre and Post ACE Scores  
INFORMED CHOICE SCORE CHANGES IN PATIENTS WITH RECENET CANCER DIAGNOSIS 
  
INFORMED CHOICE SCORE CHANGES IN PATIENTS WITH FAMILY HISTORY OF CANCER 
 
 
STATA DIFFERENCES IN INFORMED CHOICE SCORES BETWEEN PARTICIPANTS WITH CANCER AND 
PARTICIPANTS WITH FAMILY HISTORY OF CANCER OUTPUT 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
Inf~rDif |      19    .2467368    1.036673    4.518752   -1.931232    2.424705 
Inf~xDif |      19    1.151368    .8603597    3.750221   -.6561803    2.958917 
---------+-------------------------------------------------------------------- 
combined |      38    .6990526     .668576    4.121379    -.655611    2.053716 
---------+-------------------------------------------------------------------- 
    diff |           -.9046316    1.347186               -3.636851    1.827588 
------------------------------------------------------------------------------ 
    diff = mean(InformedCho~rDif) - mean(InformedCho~xDif)        t =  -0.6715 




    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.2531         Pr(|T| > |t|) = 0.5062          Pr(T > t) = 0.7469 
B.2.4 Total Pre and Post ACE Scores  
TOTAL SCORE CHANGES IN PATIENTS WITH RECENT CANCER DIAGNOSIS 
  




STATA DIFFERENCES IN TOTAL SCORES BETWEEN PARTICIPANTS WITH CANCER AND PARTICIPANTS 
WITH FAMILY HISTORY OF CANCER OUTPUT 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
TotalC~f |      19    1.069158    1.923225    8.383145   -2.971389    5.109704 
TotalF~f |      19    4.057158    1.280495    5.581546    1.366939    6.747377 
---------+-------------------------------------------------------------------- 
combined |      38    2.563158    1.165706    7.185893    .2012135    4.925102 
---------+-------------------------------------------------------------------- 
    diff |              -2.988    2.310511               -7.673934    1.697934 
------------------------------------------------------------------------------ 
    diff = mean(TotalCancerDif) - mean(TotalFHxDif)               t =  -1.2932 
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Ho: diff = 0                                     degrees of freedom =       36 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.1021         Pr(|T| > |t|) = 0.2042          Pr(T > t) = 0.8979 
B.3 DATA BETWEEN MALES AND FEMALES  
B.3.1 Commitment Pre and Post ACE Scores 
STATA DIFFERENCES IN COMMITMENT SCORES BETWEEN MALE AND FEMALE PARTICPANTS 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
MCommi~t |      13    1.803077    1.059321    3.819435   -.5049844    4.111138 
FCommi~t |      25      .18748    .6649153    3.324576   -1.184838    1.559798 
---------+-------------------------------------------------------------------- 
combined |      38    .7401842    .5736311      3.5361   -.4221028    1.902471 
---------+-------------------------------------------------------------------- 
    diff |            1.615597    1.195873               -.8097468    4.040941 
------------------------------------------------------------------------------ 
    diff = mean(MCommitment) - mean(FCommitment)                  t =   1.3510 
Ho: diff = 0                                     degrees of freedom =       36 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.9074         Pr(|T| > |t|) = 0.1851          Pr(T > t) = 0.0926 
 
 
B.3.2 Navigation Pre and Post ACE Scores 
STATA DIFFERENCES IN NAVIGATION SCORES BETWEEN MALE AND FEMALE PARTICPANTS 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
MNavig~n |      13    1.963231    1.023452    3.690109   -.2666797    4.193141 
FNavig~n |      25      .68752    .7165193    3.582596   -.7913031    2.166343 
---------+-------------------------------------------------------------------- 
combined |      38    1.123947    .5875436    3.621862    -.066529    2.314424 
---------+-------------------------------------------------------------------- 
    diff |            1.275711    1.237409               -1.233871    3.785293 
------------------------------------------------------------------------------ 
    diff = mean(MNavigation) - mean(FNavigation)                  t =   1.0310 
Ho: diff = 0                                     degrees of freedom =       36 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.8453         Pr(|T| > |t|) = 0.3094          Pr(T > t) = 0.1547 
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B.3.3 Informed Choice Pre and Post ACE Scores 
STATA DIFFERENCES IN INFORMED CHOICE SCORES BETWEEN MALE AND FEMALE PARTICPANTS 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
MInfor~e |      13    .9616924    .6974745     2.51478   -.5579741    2.481359 
FInfor~e |      25      .56248    .9584892    4.792446   -1.415744    2.540704 
---------+-------------------------------------------------------------------- 
combined |      38    .6990526     .668576    4.121379    -.655611    2.053716 
---------+-------------------------------------------------------------------- 
    diff |            .3992124    1.427154                -2.49519    3.293615 
------------------------------------------------------------------------------ 
    diff = mean(MInformedChoice) - mean(FInformedChoice)          t =   0.2797 
Ho: diff = 0                                     degrees of freedom =       36 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 




B.3.4 Total Pre and Post ACE Scores 
 
STATA DIFFERENCES IN TOTAL SCORES BETWEEN MALE AND FEMALE PARTICPANTS 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
  MTotal |      13    4.727769     1.46304    5.275067    1.540078     7.91546 
  FTotal |      25     1.43756     1.57272    7.863601   -1.808375    4.683495 
---------+-------------------------------------------------------------------- 
combined |      38    2.563158    1.165706    7.185893    .2012135    4.925102 
---------+-------------------------------------------------------------------- 
    diff |            3.290209    2.429931                -1.63792    8.218339 
------------------------------------------------------------------------------ 
    diff = mean(MTotal) - mean(FTotal)                            t =   1.3540 
Ho: diff = 0                                     degrees of freedom =       36 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 





B.4 PARTICIPANT AGE DATA  




. summarize Ages 
 
    Variable |        Obs        Mean    Std. Dev.       Min        Max 
-------------+--------------------------------------------------------- 















AGE RANGE N= NUMBER OF PARTICIPANTS 
MEAN DIFFERENCE IN 
PRE/POST TOTAL 
SCORES 
10s 1 +7.813 
30s 7 +0.223 
40s 8 +6.055 
50s 6 +1.823 
60s 9 +3.530 
70s 6 +0.260 
80s 1 -3.125 
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 84 
 
C.1 LIFESTYLE QUESTIONNAIRE, TOBACCO CESSATION 
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C.2 LIFESTYLE QUESTIONNAIRE, WEIGHT LOSS  
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C.3 DATA ACROSS LIFESTYLE PARTICIPANTS 
C.3.1 Commitment Scores in Participants who Failed to Change and Participants who 
were Successful in Change   
COMMITMENT SCORE CHANGES IN PARTICIPANTS WHO FAILED TO CHANGE LIFESTYLE BEHAVIORS 
 COMMITMENT SCORE CHANGES IN PARTICIPANTS WHO SUCCESSFULLY CHANGED LIFESTYLE BEHAVIORS 
 
 
Difference in Commitment Scores between Participants who Failed to Change and 
Participants who were Successful in Change of Lifestyle Behaviors 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
FTCCom~t |       7    2.455572    2.125498    5.623538   -2.745334    7.656477 
SCComm~t |       6    .2603333    1.421766    3.482602   -3.394433      3.9151 
---------+-------------------------------------------------------------------- 
combined |      13    1.442385      1.3057    4.707768   -1.402491    4.287261 
---------+-------------------------------------------------------------------- 
    diff |            2.195238    2.654344               -3.646933    8.037409 
------------------------------------------------------------------------------ 
    diff = mean(FTCCommitment) - mean(SCCommitment)               t =   0.8270 
Ho: diff = 0                                     degrees of freedom =       11 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.7871         Pr(|T| > |t|) = 0.4258          Pr(T > t) = 0.2129 
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C.3.2 Navigation Scores in Participants who Failed to Change and Participants who were 
Successful in Change  
NAVIGATION SCORE CHANGES IN PARTICIPANTS WHO FAILED TO CHANGE LIFESTYLE BEHAVIORS 
 
NAVIGATION SCORE CHANGES IN PARTICIPANTS WHO SUCCESSFULLY CHANGED LIFESTYLE BEHAVIORS 
 
 
Difference in Navigation Scores between Participants who Failed to Change and 
Participants who were Successful in Change of Lifestyle Behaviors 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
FTCNav~n |       7   -.4465714    .7403539    1.958792   -2.258152    1.365009 
SCNavi~n |       6    2.170167    1.801337    4.412356   -2.460317    6.800651 
---------+-------------------------------------------------------------------- 
combined |      13    .7611539    .9557107    3.445864   -1.321161    2.843469 
---------+-------------------------------------------------------------------- 
    diff |           -2.616738    1.840356               -6.667335    1.433859 
------------------------------------------------------------------------------ 
    diff = mean(FTCNavigation) - mean(SCNavigation)               t =  -1.4219 
Ho: diff = 0                                     degrees of freedom =       11 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.0914         Pr(|T| > |t|) = 0.1828          Pr(T > t) = 0.9086 
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C.3.3 Informed Choice Scores in Participants who Failed to Change and Participants who 
were Successful in Change   
INFORMED CHOICE SCORE CHANGES IN PARTICIPANTS WHO FAILED TO CHANGE LIFESTYLE BEHAVIORS 
  
INFORMED CHOICE SCORE CHANGES IN PARTICIPANTS WHO SUCCESSFULLY CHANGED LIFESTYLE 
BEHAVIORS 
  
Participants who were Successful in Change of Lifestyle Behaviors 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
FTCInf~e |       7    2.678857    .6571575    1.738675    1.070851    4.286864 
SCInfo~e |       6   -.5208333    .6588869    1.613937   -2.214556    1.172889 
---------+-------------------------------------------------------------------- 
combined |      13    1.202077    .6417054    2.313702    -.196079    2.600233 
---------+-------------------------------------------------------------------- 
    diff |            3.199691    .9364028                1.138682    5.260699 
------------------------------------------------------------------------------ 
    diff = mean(FTCInformedCho~e) - mean(SCInformedChoice)        t =   3.4170 
Ho: diff = 0                                     degrees of freedom =       11 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.9971         Pr(|T| > |t|) = 0.0058          Pr(T > t) = 0.0029 
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C.3.4 Total Scores in Participants who Failed to Change and Participants who were 
Successful in Change   
TOTAL SCORE CHANGES IN PARTICIPANTS WHO FAILED TO CHANGE LIFESTYLE BEHAVIORS 
 
TOTAL SCORE CHANGES IN PARTICIPANTS WHO SUCCESSFULLY CHANGED LIFESTYLE BEHAVIORS 
 
 
Difference in Total Scores between Participants who Failed to Change and Participants 
who were Successful in Change Lifestyle Behaviors 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
Variable |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
FTCTotal |       7    4.687714     2.97248    7.864444   -2.585683    11.96111 
 SCTotal |       6    1.909833    1.362614    3.337709   -1.592877    5.412544 
---------+-------------------------------------------------------------------- 
combined |      13    3.405615    1.701675    6.135478   -.3020165    7.113247 
---------+-------------------------------------------------------------------- 
    diff |            2.777881    3.465469               -4.849566    10.40533 
------------------------------------------------------------------------------ 
    diff = mean(FTCTotal) - mean(SCTotal)                         t =   0.8016 
Ho: diff = 0                                     degrees of freedom =       11 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.7801         Pr(|T| > |t|) = 0.4398          Pr(T > t) = 0.2199 
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